Day: March 22, 2024

TORONTO, March 22, 2024 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV:FW) (“Flow Capital” and “Company”), a leading provider of flexible growth capital and alternative debt solutions, is pleased to announce that it has completed a tranche of its previously disclosed non-convertible loan transaction in the principal amount of $2.3 million (the “Loans”). The Loans will be evidenced by unsecured, non-convertible debentures (the “Debentures”) issued by the Company to the Lenders pursuant to the terms of a debenture indenture entered between the Company and Olympia Trust Company, as debenture trustee. The net proceeds of the Loans will be used by the Company to fund investments and for general corporate purposes. About Flow Capital Flow Capital Corp. is a diversified alternative asset investor and advisor, specializing in providing minimally...

MONTRÉAL, March 22, 2024 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier”) today announced that it has successfully priced its offering of US$750 million aggregate principal amount of new Senior Notes due July 1, 2031. The new Senior Notes will carry a coupon of 7.250% per annum and will be sold at 99.75% of par (the “New Notes”). The issuance of the New Notes is expected to close on or about April 4, 2024, subject to customary closing conditions. Bombardier intends to use the proceeds of the offering of the New Notes, together with cash on hand, (i) to finance the offer to purchase (the “2026 Tender Offer”) up to US$550 million aggregate purchase amount (exclusive of accrued and unpaid interest) of its outstanding 7.125% Senior Notes due 2026 (the “2026 Notes”), of which there is US$1,001 million aggregate principal amount outstanding...

MONTRÉAL, March 22, 2024 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier”) today announced that it has issued a conditional notice of partial redemption for US$200 million principal amount of its outstanding 7.875% Senior Notes due 2027 (the “Notes”). As set forth in the conditional notice of partial redemption issued today in respect of the Notes, the redemption date is April 22, 2024 (the “Redemption Date”), and the redemption price is 100.00% of the principal amount redeemed, plus accrued and unpaid interest. The redemption of the Notes is subject to and conditioned upon Bombardier completing a new offering of debt securities in the aggregate principal amount of not less than US$750 million before the Redemption Date; however, Bombardier may delay or waive this condition in its sole and absolute discretion.  On March 22, 2024,...

LUXEMBOURG, March 22, 2024 (GLOBE NEWSWIRE) — Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) filed today its 2023 Annual Report and its 2023 Sustainability Report with the Luxembourg Stock Exchange, with the U.S. Securities and Exchange Commission (SEC), and with the other securities regulators of the markets where its securities are listed. These reports (which contain the financial and non-financial information required by applicable Luxembourg law for the year ended December 31, 2023, including Tenaris’s consolidated financial statements as of and for the year ended December 31, 2023, Tenaris’s annual accounts as at December 31, 2023, and their related external auditors’ reports and consolidated management report and certifications) is available on the Luxembourg Stock Exchange’s website at www.bourse.lu/regulated-information-oam,...

CALGARY, Alberta, March 22, 2024 (GLOBE NEWSWIRE) — DIRTT Environmental Solutions Ltd. (TSX: DRT; OTC: DRTTF), a leader in industrialized construction, announced today that its Board of Directors has adopted the shareholder rights plan announced on March 19, 2024 and has also entered into a support agreement with DIRTT’s largest shareholder, 22NW Fund, LP. As previously announced, the rights plan is substantially similar to the rights plan adopted by the Company in 2021 and is intended to limit further concentration of ownership of the company. While the rights plan has been approved by the Board of Directors with one director dissenting and is now in effect, it remains subject to shareholder ratification within six months of its adoption. The date and time of the special meeting of shareholders to ratify the rights plan will be...

ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) — AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2023 and recent highlights. Recent Highlights  ● Stockholders approved transactions for merger with Serina Therapeutics, Inc.  ● Obtained $4.4 million addition to line of credit from Juvenescence Limited  ● Preferred Stock converted into Common Stock  ● Completed reverse stock split at a ratio of 1 for 35.17     Liquidity and Capital Resources Issuance of Preferred Stock to Eliminate $36 Million of Indebtedness and Conversion to Common Stock During July 2023, AgeX and Juvenescence Limited entered into an Exchange Agreement pursuant...

VANCOUVER, British Columbia, March 22, 2024 (GLOBE NEWSWIRE) — Major Precious Metals Corp. (“Major Precious Metals” or the “Company”) has applied to the British Columbia Securities Commission (“BCSC”) for a partial revocation of the failure-to-file cease trade order (“FFCTO”) that was issued by the BCSC against the company on January 12, 2023, for failing to file certain outstanding continuous disclosure documents in a timely manner. If the partial revocation order is granted, the company intends to complete a non-brokered private placement of up to thirty million units (“Units”) issued at a price of $0.025 per Unit for gross proceeds of up to $750,000. Each Unit will be comprised of one common share (each a “Share”) and one transferable common share purchase warrant (each a “Warrant”). Each Warrant will entitle the holder thereof...

Leading Contract Research Organization to carry out pharmacological studies, part of planned FDA Investigational New Drug (IND) application TORONTO and HAIFA, Israel, March 22, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, developing regenerative medicine therapies, is proud to announce a strategic service agreement with Vivox Ltd. (“Vivox”), a leading provider of animal testing and services in Israel to biotech and pharmaceutical companies. This large-scale animal testing represents a significant step towards filing an Investigational New Drug (IND) application in the US for NurExone’s ExoPTEN therapy for spinal cord injury (SCI). Under the terms of the agreement, Vivox will provide Contract Research Organization (CRO) services to...